109 filings
Page 4 of 6
8-K
5owlhs58e 22at3rn6
29 Jul 19
Departure of Directors or Certain Officers
4:27pm
8-K
bxg534tuc1tfe
1 Jul 19
Departure of Directors or Certain Officers
5:02pm
8-K
svmkwyy6 qbqw
11 Jun 19
Results of Operations and Financial Condition
4:14pm
8-K
wj3qd afqj
6 Jun 19
Termination of a Material Definitive Agreement
7:44am
8-K
27g 6sm4m2ns
18 Apr 19
Departure of Directors or Certain Officers
5:05pm
8-K
nq00 9qeb6
21 Mar 19
Departure of Directors or Certain Officers
5:17pm
8-K
qecb0jc5 5csvokakg
15 Mar 19
Other Events
12:00am
8-K
i6l8 soc7a
20 Feb 19
Departure of Directors or Certain Officers
4:33pm
8-K
8kc7q21auojkbdd in22
7 Feb 19
Axovant Announces Third Fiscal Quarter 2018 Financial Results and Corporate Updates
5:06pm
8-K
nokmg0cv 6gps9y9e
17 Dec 18
Other Events
4:32pm
8-K
vlif87igsps darryh2
13 Dec 18
Entry into a Material Definitive Agreement
5:02pm
8-K
wqrte7plfd
7 Nov 18
Axovant Announces Second Fiscal Quarter 2018 Financial Results and Corporate Updates
12:00am
8-K
56wn5nu ytsbg97az
2 Oct 18
Departure of Directors or Certain Officers
4:16pm
8-K
r3x6aa7pg6j8lb8sj54
17 Aug 18
Submission of Matters to a Vote of Security Holders
4:27pm
8-K
g0n4lkte
7 Aug 18
Axovant Announces First Fiscal Quarter 2018 Financial Results and Corporate Update
12:00am
8-K
lojz0j6 2qh
9 Jul 18
Entry into a Material Definitive Agreement
6:13am
8-K
j7kwz5
22 Jun 18
Entry into a Material Definitive Agreement
5:28pm
8-K
3scb6 8xqp7738k
6 Jun 18
Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition
6:02am
8-K/A
g4ymvlelmqn1o oggbz3
14 Mar 18
Departure of Directors or Certain Officers
12:00am
8-K/A
6yneq
7 Mar 18
Departure of Directors or Certain Officers
12:00am